Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to HK Equities

HK Equities · Finance research note

HKEX 2633 - Jacobson Pharma Corporation Ltd.

Research and analysis only
View analysis Browse HK Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* -25.80%
Risk / Std Dev (Ann.)* 21.82%
1-Year Price Return* -26.81%

Latest Market Data (as of 2026-08-14, Hong Kong time):

Metric Value
Last Price HK$1.045
52-Week Range HK$0.98 – HK$1.56
Observation Count 245 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year price series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2026 FY2025
Revenue Reported revenue HK$1.57B HK$1.58B
Net income Reported net income HK$301.62M HK$300.83M
Total assets Year-end reported balance HK$3.56B HK$3.65B
Shareholders’ equity Year-end reported balance HK$2.32B HK$2.45B
Net margin Net income ÷ revenue 19.22% 19.08%
Asset turnover Revenue ÷ total assets 0.4404x 0.4326x
Equity multiplier Total assets ÷ shareholders’ equity 1.5388x 1.4859x
ROE Net margin × asset turnover × equity multiplier 13.02% 12.26%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue HK$1.57B
Prior annual revenue HK$1.58B
EBIT HK$393.33M
Tax rate 16.82%
NOPAT = EBIT × (1 − tax rate) HK$327.16M
Forecast start-growth basis -0.47%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT HK$327.16M
Add: depreciation & amortisation HK$153.79M
Less: capital expenditure -HK$136.19M
Less/(add): working-capital cash-flow movement -HK$150.22M
Current unlevered FCFF HK$194.54M

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 -0.47% HK$325.61M HK$153.06M -HK$135.54M -HK$149.51M HK$193.62M HK$188.93M
2 0.27% HK$326.50M HK$153.48M -HK$140.30M -HK$149.92M HK$189.76M HK$176.28M
3 1.01% HK$329.81M HK$155.04M -HK$146.16M -HK$151.44M HK$187.24M HK$165.61M
4 1.76% HK$335.60M HK$157.76M -HK$153.25M -HK$154.10M HK$186.02M HK$156.64M
5 2.50% HK$343.99M HK$161.70M -HK$161.70M -HK$157.95M HK$186.04M HK$149.15M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.22
Cost of equity 5.92%
Pre-tax cost of debt 3.65%
WACC 5.03%
WACC validation requires assumption review

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value HK$7.53B
Implied terminal EV / EBITDA 13.08x
Terminal value as % of enterprise value 87.56%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF HK$836.60M
Present value of terminal value HK$5.89B
Indicated enterprise value HK$6.72B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value HK$6.72B
Less: gross interest-bearing debt HK$910.90M
Add: cash and equivalents HK$369.86M
Add: affiliate investments HK$0.00
Less: minority interests HK$24.22M
Indicated common equity value HK$6.16B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 2,000,221,000.00
Share-count basis reported shares outstanding; option/RSU dilution data not separately available
Current market price HK$1.03
DCF indicative value per share HK$3.08
Indicative value vs. market price 198.93%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range review required
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:02:39.019719 UTC; latest reported fiscal period: 2026-03-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set Asia Pacific ex Japan
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-20 to 2026-06-30
Aligned daily observations 210
Minimum observation requirement 120
Currency conversion for HK listings HKD adjusted close divided by daily USD/HKD close before simple daily return calculation

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -36.85% -36.34%
Adjusted R² 0.05 0.04
Annualised residual volatility 21.80% 21.74%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.36 (2.90) 0.31 (2.33)
Size (SMB) 0.33 (1.79) 0.21 (0.93)
Value (HML) 0.30 (1.73) 0.37 (1.90)
Profitability (RMW) NM 0.09 (0.38)
Investment (CMA) NM -0.26 (-0.96)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

hkexstockequity2633